Company Analysis
Sign in

Curis, Inc. (CRIS)

Nasdaq: CRIS · Biological Products, (No Diagnostic Substances) · Lexington, MA · filing with the SEC since 2000
Full chart Alerts Compare
Grade4.1
◀ Past 3.4● Present 4.1▶ Future 4.5
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

142 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Curis, Inc.’s names, not what it holds today.

Patents granted
142
142 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 3 in 2024 and 3 in 2023
Applications published
120
3 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals14
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Curis, Inc. its own name
US, as the owner printed on each patent. 10 more under the same name are not counted (printed in GB)
142 granted
75 published
Curis, Inc. its own name
named as the applicant on its applications, in US
0 granted
45 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Sep 2, 202512,403,142Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moietyPharmaceuticalsCuris, Inc.
Mar 18, 202512,252,475Crystal forms of immunomodulatorsPharmaceuticalsCuris, Inc.
Dec 31, 202412,178,821Combination therapies for the treatment of cancerPharmaceuticalsCuris, Inc.
Aug 20, 202412,064,418Conjoint therapies for immunomodulationPharmaceuticalsCuris, Inc.
Mar 26, 202411,939,306Crystal forms of immunomodulatorsPharmaceuticalsCuris, Inc.
May 23, 202311,654,136Phosphoinositide 3-kinase inhibitor with a zinc binding moietyPharmaceuticalsCuris, Inc.
May 9, 202311,643,401Crystal forms of immunomodulatorsPharmaceuticalsCuris, Inc.
Mar 7, 202311,597,732Phosphoinositide 3-kinase inhibitors with a zinc binding moietyPharmaceuticalsCuris, Inc.
Nov 15, 202211,497,735Conjoint therapies for immunomodulationPharmaceuticalsCuris, Inc.
Mar 1, 202211,261,195Phosphoinositide 3-kinase inhibitors with a zinc binding moietyPharmaceuticalsCuris, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jul 17, 20252025/0230169Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding MoietyPharmaceuticalsCuris, Inc.
Jun 12, 20252025/0188045CRYSTAL FORMS OF IMMUNOMODULATORSPharmaceuticalsCuris, Inc.
Mar 13, 20252025/0082644COMBINATION THERAPIES FOR THE TREATMENT OF CANCERPharmaceuticalsCuris, Inc.
Jun 6, 20242024/0182433CRYSTAL FORMS OF IMMUNOMODULATORSPharmaceuticalsCuris, Inc. · patent 12,252,475 granted from it
Apr 11, 20242024/0116872PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLINGOrganic fine chemistryCuris, Inc.
Feb 8, 20242024/0044899BIOMARKERS FOR FIMEPINOSTAT THERAPYPharmaceuticalsCuris, Inc.
Dec 28, 20232023/0414582METHODS OF TREATING DISEASES AND DISORDERSPharmaceuticalsCuris, Inc.
Oct 5, 20232023/0310444COMPOSITIONS AND METHODS FOR TREATING DISEASES AND DISORDERSPharmaceuticalsCuris, Inc.
Aug 24, 20232023/0265054PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLINGOrganic fine chemistryCuris, Inc.
Jul 20, 20232023/0227467PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETYPharmaceuticalsCuris, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 5 · Organic fine chemistry 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton CRIS · research, not advice